Symptomatic CAUTI: with microbiological evidence ‐ antibiotic versus silver alloy · Patients with an indwelling urethral catheter of short‐term duration
Antimicrobial‐impregnated catheter leads to lower symptomatic CAUTI: with microbiological evidence ‐ antibiotic versus… compared with antiseptic‐coated catheter (high certainty).
1 finding from 1 review
Urinary sepsis · Patients with an indwelling urethral catheter of short‐term duration
1 finding from 1 review
Patient discomfort whilst catheter is in situ · Patients with an indwelling urethral catheter of short‐term duration
Antimicrobial‐impregnated catheter leads to higher patient discomfort whilst catheter is in situ compared with antiseptic‐coated catheter (high certainty).
1 finding from 1 review
Symptomatic CAUTI: with microbiological evidence ‐ nitrofurazone versus standard ‐ not reported · Patients with an indwelling urethral catheter of short‐term duration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bacterial resistance towards the antimicrobial agent ‐ not reported · Patients with an indwelling urethral catheter of short‐term duration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Urinary sepsis · Patients with an indwelling urethral catheter of short‐term duration
1 finding from 1 review
Symptomatic CAUTI: with microbiological evidence ‐ silver alloy versus standard · Patients with an indwelling urethral catheter of short‐term duration
1 finding from 1 review
Patient discomfort whilst catheter is in situ Number with burning sensation in urethra ‐ Silicone versus non‐silicone · Patients with an indwelling urethral catheter of short‐term duration
1 finding from 1 review
Symptomatic CAUTI: without microbiological evidence ‐ nitrofurazone versus standard ‐ not reported · Patients with an indwelling urethral catheter of short‐term duration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bacterial resistance towards the antimicrobial agent ‐ not reported · Patients with an indwelling urethral catheter of short‐term duration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Urinary sepsis ‐ not reported · Patients with an indwelling urethral catheter of short‐term duration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient discomfort whilst catheter is in situ · Patients with an indwelling urethral catheter of short‐term duration
2 findings from 1 review
Symptomatic CAUTI: without microbiological evidence ‐ nitrofurazone versus standard · Patients with an indwelling urethral catheter of short‐term duration
1 finding from 1 review
Symptomatic CAUTI: with microbiological evidence ‐ nitrofurazone versus standard · Patients with an indwelling urethral catheter of short‐term duration
1 finding from 1 review
Bacterial resistance towards the antimicrobial agent ‐ not reported · Patients with an indwelling urethral catheter of short‐term duration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations needing hospitalisation · people with asthma
Formoterol showed no clear difference in patients with an exacerbation requiring hospitalisation compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · people with asthma
Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · people with asthma
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Patients with a serious adverse event (all cause) · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Asthma‐related serious adverse event · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (asthma related) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review